Dr. Kamdar is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2190 E 11th Avenue
2190 E 11th Avenue
Denver, CO 80206Phone+1 252-847-4268
Education & Training
- Vidant Medical Center/East Carolina UniversityFellowship, Hematology and Medical Oncology, 2010 - 2013
- ECU Health Medical Center/East Carolina UniversityResidency, Internal Medicine, 2007 - 2010
- KJ Somaiya Medical CollegeClass of 2004
Certifications & Licensure
- CA State Medical License 2013 - Present
- CO State Medical License 2014 - 2025
- WY State Medical License 2021 - 2025
- NC State Medical License 2007 - 2013
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma Start of enrollment: 2020 Nov 23
- POLA+BR for Relapsed or Refractory DLBCL Start of enrollment: 2021 Jan 29
Publications & Presentations
PubMed
- Outcomes Among Adult Recipients of CAR T-cell Therapy for Burkitt Lymphoma.Laura Samples, Hossein Sadrzadeh, Matthew J Frigault, Caron A Jacobson, Mehdi Hamadani
Blood. 2025-02-12 - Correction: Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambuci...Jeff P Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M Pagel
Leukemia. 2025-02-01 - DA-R-EPOCH May Mitigate the Adverse Prognostic Implication of the Diagnosis-to-Treatment Interval (DTI) in Large B-Cell Lymphomas.Jessica Allen, Diana Abbott, Joy Eskandar, Steven M Bair, Bradley Haverkos
Clinical Lymphoma, Myeloma & Leukemia. 2025-01-01
Abstracts/Posters
- The Evaluation and Treatment (Tx) of Burkitt Lymphoma (BL) in the Modern Era: Real World (RW) Outcomes and Prognostication across 26 US Cancer Centers (CC)Manali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 1 Study of ALX148, a CD47 Blocker, in Combination with Rituximab in Patients with Non-Hodgkin LymphomaManali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Polatuzumab Vedotin Plus Bendamustine with Rituximab in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Updated Results of a Phase Ib/II Randomized StudyManali Kamdar, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Lectures
- Five-Year Outcomes of SWOG S0: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine Followed By Autologous Stem Cell Transplant for Patients with Ma...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Res...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- A Phase I Study of Molibresib (GSK525762), a Selective Bromodomain (BRD) and Extra Terminal Protein (BET) Inhibitor: Results from Part 1 of a Phase I/II Open Label Sin...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
- CU Anschutz Steps Back into the Spotlight with New Marketing CampaignFebruary 5th, 2025
- School of Medicine Honors Distinguished CliniciansMarch 29th, 2023
- Why Is CAR T-cell Therapy ‘One of the Most Phenomenal Advances in Science’?August 16th, 2022
- Join now to see all
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: